ATG5 and non-small cell lung carcinoma: Furthermore, due to concerns about off-target effects of clarithromycin, ATG5 silencing, which was accompanied by increased p62/SQSTM1 and a decrease in the LC3I/II conversion, resulted in a significant reduction in cell migration and invasion over and above that induced by gefitinib alone, as well as an increase in gefitinib sensitivity in NSCLC-resistant cell lines [77].